Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 20 of 416

1.

Multiple Myeloma as the Underlying Cause of Thrombotic Microangiopathy Leading to Acute Kidney Injury: Revisiting a Very Rare Entity.

Chugh S, Kichloo A, Jafri F, Yusvirazi L, Lerner R.

J Investig Med High Impact Case Rep. 2017 Sep 22;5(3):2324709617732797. doi: 10.1177/2324709617732797. eCollection 2017 Jul-Sep.

2.

Beta-adrenergic receptors are expressed across diverse cancers.

Rains SL, Amaya CN, Bryan BA.

Oncoscience. 2017 Aug 23;4(7-8):95-105. doi: 10.18632/oncoscience.357. eCollection 2017 Jul.

3.

Plasma Cell Infiltration of the Kidney as a Manifestation of Myeloma: A Report of Three Cases.

Kaur T, Krishnaprasad S, Shankar R, Kumar R, Gowrishankar S, Padua MD.

Indian J Nephrol. 2017 Sep-Oct;27(5):395-398. doi: 10.4103/ijn.IJN_215_16.

4.

Kidney Transplantation in Patients With Active Multiple Myeloma: Case Reports.

Lum EL, Kogut N, Pham T, Danovitch GM, Bunnapradist S.

Transplant Direct. 2017 Jul 21;3(8):e200. doi: 10.1097/TXD.0000000000000716. eCollection 2017 Aug.

5.

Sequential, Autologous Hematopoietic Stem Cell Transplant Followed by Renal Transplant in Multiple Myeloma.

Bhowmik D, Yadav S, Kumar L, Agarwal S, Agarwal SK, Gupta S.

Indian J Nephrol. 2017 Jul-Aug;27(4):324-326. doi: 10.4103/ijn.IJN_169_16.

6.

Obesity and orthodontic treatment: is there any direct relationship?

Consolaro A.

Dental Press J Orthod. 2017 May-Jun;22(3):21-25. doi: 10.1590/2177-6709.22.3.021-025.oin.

7.

[177Lu]pentixather: Comprehensive Preclinical Characterization of a First CXCR4-directed Endoradiotherapeutic Agent.

Schottelius M, Osl T, Poschenrieder A, Hoffmann F, Beykan S, Hänscheid H, Schirbel A, Buck AK, Kropf S, Schwaiger M, Keller U, Lassmann M, Wester HJ.

Theranostics. 2017 Jun 11;7(9):2350-2362. doi: 10.7150/thno.19119. eCollection 2017.

8.

Multiple myeloma can be accurately diagnosed in acute kidney injury patients using a rapid serum free light chain test.

Heaney JLJ, Campbell JP, Yadav P, Griffin AE, Shemar M, Pinney JH, Drayson MT.

BMC Nephrol. 2017 Jul 20;18(1):247. doi: 10.1186/s12882-017-0661-z.

9.

Long-term renal survival of γ3-heavy chain deposition disease: a case report.

Katsuno T, Mizuno S, Mabuchi M, Tsuboi N, Komatsuda A, Maruyama S.

BMC Nephrol. 2017 Jul 17;18(1):239. doi: 10.1186/s12882-017-0645-z.

10.

Rediscovering Beta-2 Microglobulin As a Biomarker across the Spectrum of Kidney Diseases.

Argyropoulos CP, Chen SS, Ng YH, Roumelioti ME, Shaffi K, Singh PP, Tzamaloukas AH.

Front Med (Lausanne). 2017 Jun 15;4:73. doi: 10.3389/fmed.2017.00073. eCollection 2017. Review.

11.

Plasma cell neoplasia after kidney transplantation: French cohort series and review of the literature.

Kormann R, François H, Moles T, Dantal J, Kamar N, Moreau K, Bachelet T, Heng AE, Garstka A, Colosio C, Ducloux D, Sayegh J, Savenkoff B, Viglietti D, Sberro R, Rondeau E, Peltier J.

PLoS One. 2017 Jun 21;12(6):e0179406. doi: 10.1371/journal.pone.0179406. eCollection 2017. Review.

12.

Renal impairment and use of nephrotoxic agents in patients with multiple myeloma in the clinical practice setting in the United States.

Qian Y, Bhowmik D, Bond C, Wang S, Colman S, Hernandez RK, Cheng P, Intorcia M.

Cancer Med. 2017 Jul;6(7):1523-1530. doi: 10.1002/cam4.1075. Epub 2017 Jun 14.

13.

Immunoglobulin A Lambda Multiple Myeloma in a Patient with HIV: An Unusual Cause of Massive Ascites.

Abdulsamad M, Abbas N, Patel H, Balar B, Khaja M.

Case Rep Gastroenterol. 2017 Apr 10;11(1):201-206. doi: 10.1159/000468516. eCollection 2017 Jan-Apr.

14.

Light chain Fanconi syndrome in a patient with acute myeloid leukemia and monoclonal gammopathy of undetermined significance.

Ross DW, Wanchoo R, Guigova A, Ghiuzeli C, Allen SL, Jhaveri KD.

CEN Case Rep. 2016 Nov;5(2):238-241. doi: 10.1007/s13730-016-0232-3. Epub 2016 Aug 30.

15.

Successful treatment of myeloma cast nephropathy using bortezomib-based chemotherapy plus selective plasma exchange.

Kawabe M, Yamamoto I, Katsuma A, Hayashi N, Komatsuzaki Y, Nakada Y, Shimizu A, Tanno Y, Ohkido I, Tsuboi N, Suzuki K, Shimada T, Ogasawara Y, Sugiyama K, Aiba K, Yokoo T.

CEN Case Rep. 2016 Nov;5(2):232-237. doi: 10.1007/s13730-016-0231-4. Epub 2016 Aug 11.

16.

Utilizing BMP-2 muteins for treatment of multiple myeloma.

Seher A, Lagler C, Stühmer T, Müller-Richter UDA, Kübler AC, Sebald W, Müller TD, Nickel J.

PLoS One. 2017 May 10;12(5):e0174884. doi: 10.1371/journal.pone.0174884. eCollection 2017.

17.

Herpes zoster risk after 21 specific cancers: population-based case-control study.

Hansson E, Forbes HJ, Langan SM, Smeeth L, Bhaskaran K.

Br J Cancer. 2017 Jun 6;116(12):1643-1651. doi: 10.1038/bjc.2017.124. Epub 2017 May 2.

18.

Pharmacokinetics and safety of carfilzomib in patients with relapsed multiple myeloma and end-stage renal disease (ESRD): an open-label, single-arm, phase I study.

Quach H, White D, Spencer A, Ho PJ, Bhutani D, White M, Inamdar S, Morris C, Ou Y, Gyger M.

Cancer Chemother Pharmacol. 2017 Jun;79(6):1067-1076. doi: 10.1007/s00280-017-3287-8. Epub 2017 Apr 19.

19.

The risk of renal disease is increased in lambda myeloma with bone marrow amyloid deposits.

Kozlowski P, Montgomery S, Befekadu R, Hahn-Strömberg V.

J Blood Med. 2017 Mar 6;8:29-34. doi: 10.2147/JBM.S129516. eCollection 2017.

20.

Tumor Cell-Derived Microvesicles Induced Not Epithelial-Mesenchymal Transition but Apoptosis in Human Proximal Tubular (HK-2) Cells: Implications for Renal Impairment in Multiple Myeloma.

Zhao A, Kong F, Liu CJ, Yan G, Gao F, Guo H, Guo AY, Chen Z, Li Q.

Int J Mol Sci. 2017 Feb 27;18(3). pii: E513. doi: 10.3390/ijms18030513.

Supplemental Content

Loading ...
Support Center